179 related articles for article (PubMed ID: 21602900)
1. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors.
Majhail NS; Brunstein CG; Shanley R; Sandhu K; McClune B; Oran B; Warlick ED; Wagner JE; Weisdorf DJ
Bone Marrow Transplant; 2012 Apr; 47(4):494-8. PubMed ID: 21602900
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
[TBL] [Abstract][Full Text] [Related]
3. Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy.
Konuma T; Itonaga H; Shimomura Y; Fujioka M; Aoki K; Uchida N; Onizuka M; Jinguji A; Tanaka M; Ueda Y; Katayama Y; Sawa M; Tanaka H; Nakamae H; Kawakita T; Maruyama Y; Takahashi S; Ishimaru F; Kanda J; Ichinohe T; Atsuta Y
Hematol Oncol; 2024 Jan; 42(1):e3217. PubMed ID: 37592904
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.
Konuma T; Yamasaki S; Ishiyama K; Mizuno S; Hayashi H; Uchida N; Shimabukuro M; Tanaka M; Kuriyama T; Onizuka M; Ishiwata K; Sawa M; Tanaka T; Ohigashi H; Fujiwara SI; Matsuoka KI; Ota S; Nishida T; Kanda Y; Fukuda T; Atsuta Y; Nakasone H; Yanada M;
Transplant Cell Ther; 2024 Feb; 30(2):215.e1-215.e18. PubMed ID: 38081415
[TBL] [Abstract][Full Text] [Related]
5. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
Tsai SB; Rhodes J; Liu H; Shore T; Bishop M; Cushing MM; Gergis U; Godley L; Kline J; Larson RA; Mayer S; Odenike O; Stock W; Wickrema A; van Besien K; Artz AS
Biol Blood Marrow Transplant; 2018 May; 24(5):997-1004. PubMed ID: 29288821
[TBL] [Abstract][Full Text] [Related]
6. Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single-center retrospective study.
Huang J; Huang F; Fan Z; Xu N; Xuan L; Liu H; Shi P; Jiang L; Zhang Y; Sun J; Liu Q
Cancer Med; 2020 Sep; 9(17):6244-6255. PubMed ID: 32686915
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of umbilical cord blood transplantation and hematopoietic stem cell transplantation from HLA-matched sibling donors in the treatment of myelodysplastic syndrome-EB or acute myeloid leukemia with myelodysplasia-related changes].
Zhu J; Tang BL; Song KD; Zhang XH; Zhu XY; Yao W; Wan X; Liu HL; Sun ZM
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):294-300. PubMed ID: 31104440
[No Abstract] [Full Text] [Related]
8. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.
Peffault de Latour R; Brunstein CG; Porcher R; Chevallier P; Robin M; Warlick E; Xhaard A; Ustun C; Larghero J; Dhedin N; Mohty M; Socié G; Weisdorf D
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1355-60. PubMed ID: 23791622
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil.
Tavares RCB; Bonfim CS; Seber A; Pereira Lermontov S; Coulturato V; Zecchin VG; Ribeiro L; Fernandes JF; Daudt LE; Grecco CS; Darrigo-Jr LG; Villela N; Nichele S; Gouveia R; Bouzas LF; Hamerschlak N; Vigorito AC; da Silva PM; da Silva PO; da Silva CC; de Souza Fernandez C; Flowers ME; Arcuri LJ
Pediatr Transplant; 2020 Nov; 24(7):e13789. PubMed ID: 32757316
[TBL] [Abstract][Full Text] [Related]
10. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
11. Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China.
Tang X; Chen J; Fang J; Sun X; Qin MQ; Li J; Zhu Y; Luan Z
Pediatr Transplant; 2015 Jun; 19(4):413-21. PubMed ID: 25903451
[TBL] [Abstract][Full Text] [Related]
12. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
Malard F; Milpied N; Blaise D; Chevallier P; Michallet M; Lioure B; Clément L; Hicheri Y; Cordonnier C; Huynh A; Yakoub-Agha I; Peffault de Latour R; Mohty M
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1059-67. PubMed ID: 25708220
[TBL] [Abstract][Full Text] [Related]
13. Transfusion burden following reduced intensity allogeneic hematopoietic cell transplantation: Impact of donor type.
Subramanian S; Cohn C; DeFor T; Welbig J; Brunstein C; El Jurdi N; Weisdorf D
Transfusion; 2021 Jul; 61(7):2064-2074. PubMed ID: 33899243
[TBL] [Abstract][Full Text] [Related]
14. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?
Konuma T; Itonaga H; Ishiyama K; Doki N; Uchida N; Sawa M; Katayama Y; Tanaka M; Ueda Y; Onizuka M; Miyakoshi S; Ozawa Y; Fukuda T; Matsuoka KI; Tanaka J; Kimura T; Ichinohe T; Atsuta Y
Bone Marrow Transplant; 2023 Aug; 58(8):893-906. PubMed ID: 37156881
[TBL] [Abstract][Full Text] [Related]
15. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.
Ballen KK; Joffe S; Brazauskas R; Wang Z; Aljurf MD; Akpek G; Dandoy C; Frangoul HA; Freytes CO; Khera N; Lazarus HM; LeMaistre CF; Mehta P; Parsons SK; Szwajcer D; Ustun C; Wood WA; Majhail NS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1819-27. PubMed ID: 25064747
[TBL] [Abstract][Full Text] [Related]
16. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party.
Robin M; Ruggeri A; Labopin M; Niederwieser D; Tabrizi R; Sanz G; Bourhis JH; van Biezen A; Koenecke C; Blaise D; Tischer J; Craddock C; Maillard N; Mohty M; Russel N; Schetelig J; Finke J; Gluckman E; de Witte TM; Rocha V; Kroger N
Biol Blood Marrow Transplant; 2015 Mar; 21(3):489-95. PubMed ID: 25529382
[TBL] [Abstract][Full Text] [Related]
17. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
18. MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.
Pourhassan H; DeFor T; Trottier B; Dolan M; Brunstein C; Bejanyan N; Ustun C; Warlick ED
Bone Marrow Transplant; 2017 Apr; 52(4):532-538. PubMed ID: 27941767
[TBL] [Abstract][Full Text] [Related]
19. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.
Weisdorf D; Eapen M; Ruggeri A; Zhang MJ; Zhong X; Brunstein C; Ustun C; Rocha V; Gluckman E
Biol Blood Marrow Transplant; 2014 Jun; 20(6):816-22. PubMed ID: 24582782
[TBL] [Abstract][Full Text] [Related]
20. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
